Activating regulatory T cells



A Belgian start-up company, Dualyx NV, has raised €40 million in Series A financing to start clinical development of a new antibody therapeutic for autoimmune diseases. The antibody, DT-001, is an agonist of a receptor found on immune cells which is widely regarded as a master control switch in immune modulation. By agonising this receptor, DT-001 has been shown to activate regulatory T cells (Tregs) which keep the immune system from becoming overactive. The receptor is tumour necrosis factor receptor 2.